An Open-Label, Non-Randomized, 2-Period, Single Center Study to Assess the Single Dose Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone and in Combination With Rifampicin.
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2016
At a glance
- Drugs Fostamatinib (Primary) ; Rifampicin
- Indications Haematological malignancies; Rheumatoid arthritis; Tuberculosis; Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 06 Jan 2016 Results of this and other two phase I studies published in the Drugs in R and D
- 21 Jul 2011 Actual end date July 2011 added as reported by ClinicalTrials.gov.
- 21 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.